Ingalls & Snyder LLC reduced its holdings in shares of Zimmer Biomet Holdings Inc (NYSE:ZBH) by 25.0% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 4,721 shares of the medical equipment provider’s stock after selling 1,575 shares during the quarter. Ingalls & Snyder LLC’s holdings in Zimmer Biomet were worth $526,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in ZBH. MainStreet Investment Advisors LLC raised its holdings in Zimmer Biomet by 8.9% in the 2nd quarter. MainStreet Investment Advisors LLC now owns 4,881 shares of the medical equipment provider’s stock valued at $544,000 after acquiring an additional 399 shares in the last quarter. Bradley Foster & Sargent Inc. CT raised its holdings in Zimmer Biomet by 6.7% in the 2nd quarter. Bradley Foster & Sargent Inc. CT now owns 6,773 shares of the medical equipment provider’s stock valued at $755,000 after acquiring an additional 423 shares in the last quarter. TD Asset Management Inc. raised its holdings in Zimmer Biomet by 0.7% in the 2nd quarter. TD Asset Management Inc. now owns 61,859 shares of the medical equipment provider’s stock valued at $6,894,000 after acquiring an additional 425 shares in the last quarter. MUFG Americas Holdings Corp raised its holdings in Zimmer Biomet by 18.0% in the 2nd quarter. MUFG Americas Holdings Corp now owns 2,906 shares of the medical equipment provider’s stock valued at $324,000 after acquiring an additional 443 shares in the last quarter. Finally, UMB Bank N A MO raised its holdings in shares of Zimmer Biomet by 4.5% during the 2nd quarter. UMB Bank N A MO now owns 10,467 shares of the medical equipment provider’s stock worth $1,167,000 after buying an additional 455 shares in the last quarter. Institutional investors and hedge funds own 87.19% of the company’s stock.

In other Zimmer Biomet news, VP Tony W. Collins sold 2,778 shares of the company’s stock in a transaction dated Tuesday, July 31st. The stock was sold at an average price of $125.77, for a total value of $349,389.06. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 0.71% of the company’s stock.

A number of equities analysts have recently commented on ZBH shares. Zacks Investment Research cut Zimmer Biomet from a “hold” rating to a “sell” rating in a report on Tuesday, July 17th. Argus cut Zimmer Biomet from a “buy” rating to a “hold” rating in a report on Friday, June 22nd. Robert W. Baird boosted their price target on Zimmer Biomet from $121.00 to $132.00 and gave the stock a “neutral” rating in a report on Monday, July 30th. Needham & Company LLC boosted their price target on Zimmer Biomet from $146.00 to $150.00 and gave the stock a “strong-buy” rating in a report on Monday, July 30th. Finally, Citigroup boosted their price target on Zimmer Biomet from $117.00 to $128.00 and gave the stock a “neutral” rating in a report on Tuesday, July 31st. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and fifteen have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $135.10.

NYSE ZBH opened at $123.77 on Friday. Zimmer Biomet Holdings Inc has a 12 month low of $104.28 and a 12 month high of $129.34. The stock has a market capitalization of $25.64 billion, a price-to-earnings ratio of 15.41, a P/E/G ratio of 2.29 and a beta of 1.13. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.25 and a current ratio of 2.41.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Friday, July 27th. The medical equipment provider reported $1.92 EPS for the quarter, beating analysts’ consensus estimates of $1.88 by $0.04. Zimmer Biomet had a return on equity of 13.53% and a net margin of 21.67%. The firm had revenue of $2.01 billion for the quarter, compared to analyst estimates of $1.99 billion. During the same quarter in the previous year, the company posted $2.08 EPS. The business’s revenue was up 3.0% on a year-over-year basis. equities research analysts expect that Zimmer Biomet Holdings Inc will post 7.67 EPS for the current year.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.

Featured Article: How Do Tariffs Affect Trade Balances?

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings Inc (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.